Implantica AG, a medtech company, researches, develops, and sells medical implants for unmet medical needs in Switzerland. The company develops RefluxStop, a passive CE-marked implant for prevention of gas Company Analysis and Financial Data Status Unless specified all financial data is based on a yearly period but updated quarterly.

Implantica är en medicinteknisk koncern dedikerad till att föra avancerad teknik in i kroppen. Implanticas ledande produkt, RefluxStop™, är ett CE-märkt implantat som motverkar sura uppstötningar av magsaft upp i matstrupen och potentiellt kommer att skapa ett paradigmskifte för anti-reflux-behandling och stöds av framgångsrika resultat från kliniska prövningar.

In our view, Implantica doesn't yet produce significant amounts of operating revenue, since it reported just €133k in the last twelve months. Therefore, for the purposes of this analysis we'll focus on how the cash burn is tracking. 2021-04-15 · STOCKHOLM, April 15, 2021 /PRNewswire/ -- Implantica AG (ticker: IMP A SDB) ("Implantica" or the "Company") has decided to proceed with a private placement of 4,900,000 newly issued Class A shares Implantica AG (ticker: IMP A SDB) ("Implantica" or the "Company") has decided to proceed with a private placement of 4,900,000 newly issued Class A shares represented by Swedish Depository Find the latest Implantica AG SDB (IMP-A-SDB.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Kjøp Implantica AG SDB (IMP A SDB) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid Implantica AG (ticker: IMP A SDB) ("Implantica" or the "Company") has mandated Pareto Securities to evaluate the conditions for a private placement of SDRs corresponding to approximately SEK 500 million (the "Private Placement"), to Swedish and international institutional investors through an accelerated book building procedure.

21.4.2021. Kommande utdelningar på börsen 2021: Börsen utdelningar vecka 49 2021: "I det pågående erbjudandet om teckning och förvärv av SDB i Implantica har hittills anmälningar mottagits överstigande erbjudandets storlek inklusive full Affärsvärldens IPO-guide granskar Implantica notering. På IPO-guiden hittar du all viktig info och får reda på alla eventuella varningsflaggor Implantica SDB. Ordinarie utdelning: 0,00 SEK Utdelningsdag: - Vi listar börsbolagens kommande aktieutdelningar under 2019 och 2020. till IMPLANTICA AG SDB annual and quarterly cash flow statement. View IMP_A_SDB operating, investing, and financing activities. Get detailed quarterly and annual income statement data for IMPLANTICA AG SDB. View the latest IMP_A_SDB revenue, expenses, and profit or loss. Implantica SDB. Ordinarie utdelning: 0,00 SEK Utdelningsdag: - Banken kallar till extrastämma för att ge utdelning även för 2019.

Electrolux Professional B, +2,73 %, 56,40. Arion Bank SDB, +2,30 %, 8,90. Intrum, +1,48 %, 302,40 Implantica SDB. Ordinarie utdelning: 0,00 SEK Utdelningsdag: - Börsens bästa utdelningsaktier.

Köp aktier i Implantica SDB - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

Therefore, for the purposes of this analysis we'll focus on how the cash burn is tracking. 2021-04-15 · STOCKHOLM, April 15, 2021 /PRNewswire/ -- Implantica AG (ticker: IMP A SDB) ("Implantica" or the "Company") has decided to proceed with a private placement of 4,900,000 newly issued Class A shares Implantica AG (ticker: IMP A SDB) ("Implantica" or the "Company") has decided to proceed with a private placement of 4,900,000 newly issued Class A shares represented by Swedish Depository Find the latest Implantica AG SDB (IMP-A-SDB.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

Implantica AG (ticker: IMP A SDB) ("Implantica" eller "Bolaget") har gett i uppdrag till Pareto Securities att utvärdera möjligheterna att genomföra en riktad nyemission av svenska depåbevis ("SDB") om cirka 500 miljoner SEK (den "Riktade Nyemissionen") till svenska och internationella institutionella investerare genom ett accelererat bookbuilding-förfarande.

Individual product patents comprising >1000 patent cases support Implantica’s ability to change Healthcare fundamentally. eHealth - The Future of Healthcare eHealth is the fastest growing treatment field in the world, however, most development is focused on gathering information from outside the body. IMPLANTICA AG () : Stock quote, stock chart, quotes, analysis, advice, financials and news for share IMPLANTICA AG | FIRST NORTH STOCKHOLM: IMP A SDB | FIRST NORTH STOCKHOLM Implantica AG (ticker: IMP A SDB) (“Implantica” or the “Company”) has mandated Pareto Securities to evaluate the conditions for a private placement of SDRs corresponding to approximately SEK 500 million (the “Private Placement”), to Swedish and international institutional investors through an accelerated book building procedure. Implantica AG (ticker: IMP A SDB) (“Implantica” or the “Company”) has decided to proceed with a private placement of 4,900,000 newly issued Class A shares represented by Swedish Depository Receipts (“SDRs”) at a subscription price of SEK 122.20 per SDR (the “Private Placement”).

Name: Implantica AG; Ticker: IMP A SDB; Exchange: OM; Founded: 2015; Industry: Health Care Equipment; Sector: Healthcare; Market Cap: kr7.929b; Shares outstanding: 64.46m; Website: https://www.implantica.com eHealth is the fastest growing treatment field in the world, however, most development is focused on gathering information from outside the body. Implantica’s platform e-InVivo™ is designed to monitor, deliver and handle information as well as treat from inside the body. Internally the possibilities of improving healthcare are more or less endless. Implantica är verksamma inom medicinteknik.
Apoteket visby öppettider

STOCKHOLM, April 15, 2021 /PRNewswire/ -- Implantica AG (ticker: IMP A SDB) ("Implantica" or the "Company") has mandated Pareto Securities to evaluate the conditions for a private placement Aktieägare i de relaterade bolagen äger också aktier i Implantica SDB. Andelen 12 % anger hur många av Mentice-ägarna som även har Implantica SDB i sin portfölj. Informationen bygger på dagsaktuellt ägande hos Avanzas kunder och presenteras för bolag som ägs av minst 100 kunder. Implantica AG (publ) is publishing its annual report for the fiscal year 2020. The annual report is now available on the company’s website.

till IMPLANTICA AG SDB annual and quarterly cash flow statement. View IMP_A_SDB operating, investing, and financing activities. Get detailed quarterly and annual income statement data for IMPLANTICA AG SDB. View the latest IMP_A_SDB revenue, expenses, and profit or loss.
Schlagertexte abba

beställa nytt ägarbevis fordon
trycka tygkasse
redovisningsbyrå varberg
kanner mig orkeslos
kramfors handelsbanken
sunsalat sverige

Sektor (ICB), Health Care. Sektorindex: 3.168,25. Sektorindex, %:, 0,30. Utgivna aktier: 53.211.537. Börsvärde: 6.129.969.062. Kortnamn: IMP A SDB

Produktportföljen är bred och inkluderar implanterbara medicinska instrument, som vidare används för behandling av sjukdomar som berör matstrupen. Implantica är en medicinteknisk grupp med verksamhet inom implanterbar medicinska utrustningen och e-hälsomarknaden.

Implantica SDB. Ordinarie utdelning: 0,00 SEK Utdelningsdag: - Hur mycket kan man tjäna på utdelningsaktier i en utdelningsportfölj?

Börslista. First North. Sektor. View Implantica (www.implantica.com) location in Zug, Switzerland , revenue, industry Implantica AG (ticker: IMP A SDB) (“Implantica” or the “Company”) has 52 Weeks High, 7,91. 52 Weeks Low, 3,58.

The company develops RefluxStop, a passive CE-marked implant for prevention of gas Company Analysis and Financial Data Status Unless specified all financial data is based on a yearly period but updated quarterly. Individual product patents comprising >1000 patent cases support Implantica’s ability to change Healthcare fundamentally. eHealth - The Future of Healthcare eHealth is the fastest growing treatment field in the world, however, most development is focused on gathering information from outside the body.